Evidence map›Paper›PMID 23795984›Full record

ArticleAmerican journal of ophthalmology2013

Risk of choroidal neovascularization among the uveitides.

Sally L Baxter, Maxwell Pistilli, Siddharth S Pujari, Teresa L Liesegang, Eric B Suhler, Jennifer E Thorne, C Stephen Foster, Douglas A Jabs, Grace A Levy-Clarke, Robert B Nussenblatt and 2 more

Abstract readMulticenter Study
In one paragraph

Article in American journal of ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Twelve-month functional and structural outcomes ofFrontiers in cellular and infection microbiology · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Immune Cells in Subretinal Wound Healing and Fibrosis.Frontiers in cellular neuroscience · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Optical coherence tomography angiography in uveitis.Journal of ophthalmic inflammation and infection · 2019
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Sally L BaxterThe Scheie Eye Institute, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Maxwell PistilliCenter for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Siddharth S PujariMassachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts; Vasan Eye Care Hospital, Belgaum, Karnataka, India.
Teresa L LiesegangDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon.
Eric B SuhlerDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon; Department of Medicine, Oregon Health and Science University, Portland, Oregon; Portland Veterans Affairs Medical Center, Portland, Oregon.
Jennifer E ThorneDepartment of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
C Stephen FosterMassachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Douglas A JabsDepartment of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; Department of Ophthalmology, The Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medicine, The Icahn School of Medicine at Mount Sinai, New York, New York.
Grace A Levy-ClarkeLaboratory of Immunology, National Eye Institute, Bethesda, Maryland; Johnson & Johnson, New Brunswick, New Jersey.
Robert B NussenblattLaboratory of Immunology, National Eye Institute, Bethesda, Maryland.
James T RosenbaumDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon; Department of Medicine, Oregon Health and Science University, Portland, Oregon; Devers Eye Institute, Legacy Health Systems, Portland, Oregon.
John H KempenThe Scheie Eye Institute, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: john.kempen@uphs.upenn.edu.
Oregon Health & Science University · USUniversity of Pennsylvania · USHarvard University · USJohns Hopkins Medicine · USJohns Hopkins University · USJohnson & Johnson (United States) · USMassachusetts Eye Research and Surgery Institute · USNational Eye Institute · USPenn Presbyterian Medical Center · USPortland VA Medical Center · US

Funding

Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
Diagnosis And Treatment Of Ocular Inflammatory Disease (uveitis)ZIAEY000356 · NEI · NATIONAL EYE INSTITUTE · PI SEN, HATICE · 2009 to 2016
$2.7M
Complications of Immunosupression for Eye DiseasesR56EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2009 to 2009
$159k
Intramural NIH HHSNEI NIH HHS EY014943NEI NIH HHS R01 EY014943NEI NIH HHS R56 EY014943
6 · The paper itself

Abstract

purposeTo evaluate the risk, risk factors, and visual impact of choroidal neovascularization (CNV) in uveitis cases.

designRetrospective cohort study.

methodsStandardized medical record review at 5 tertiary centers.

resultsAmong 15,137 uveitic eyes (8868 patients), CNV was rare in the cases of anterior or intermediate uveitis. Among the 4041 eyes (2307 patients) with posterior uveitis or panuveitis, 81 (2.0%) had CNV at presentation. Risk factors included posterior uveitis in general and specific uveitis syndromes affecting the outer retina-retinal pigment epithelium-choroid interface. Among the 2364 eyes (1357 patients) with posterior uveitis or panuveitis and free of CNV at the time of cohort entry, the cumulative 2-year incidence of CNV was 2.7% (95% confidence interval [CI], 1.8% to 3.5%). Risk factors for incident CNV included currently active inflammation (adjusted hazard ratio [aHR], 2.13; 95% CI, 1.26 to 3.60), preretinal neovascularization (aHR, 3.19; 95% CI, 1.30 to 7.80), and prior diagnosis of CNV in the contralateral eye (aHR, 5.79; 95% CI, 2.77 to 12.09). Among specific syndromes, the incidence was greater in Vogt-Koyanagi-Harada syndrome (aHR, 3.37; 95% CI, 1.52 to 7.46) and punctate inner choroiditis (aHR, 8.67; 95% CI, 2.83 to 26.54). Incident CNV was associated with a 2-line loss of visual acuity (+0.19 logarithm of the minimal angle of resolution units; 95% CI, 0.079 to 0.29) from the preceding visit.

conclusionsCNV is an uncommon complication of uveitis associated with visual impairment that occurs more commonly in forms affecting the outer retina-retinal pigment epithelium-choroid interface, during periods of inflammatory activity, in association with preretinal neovascularization, and in second eyes of patients with unilateral CNV. Because CNV is treatable, a systematic approach to early detection in high-risk patients may be appropriate.

Indexed as

AdultChoroidal NeovascularizationFemaleHumansIncidenceMaleOdds RatioPrevalenceRetrospective StudiesRisk AssessmentRisk FactorsUnited StatesUveitisVision DisordersVisual Acuity

Identifiers

PMID23795984
PMCPMC3748230
OpenAlexW2075820715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.